tiprankstipranks
Trending News
More News >
U.s. Physical Therapy (USPH)
NYSE:USPH
Advertisement

US Physical Therapy (USPH) AI Stock Analysis

Compare
137 Followers

Top Page

USPH

US Physical Therapy

(NYSE:USPH)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
$90.00
▲(7.91% Upside)
US Physical Therapy's overall score reflects strong earnings call outcomes and stable financial performance, despite valuation concerns and technical indicators suggesting caution. The company's ability to generate cash flow and improve operational metrics supports its growth potential, while challenges like Medicare rate reductions and staffing issues pose risks.
Positive Factors
Revenue Growth
The 17.3% increase in physical therapy revenues indicates strong demand and effective market penetration, supporting long-term growth potential and competitive positioning in the healthcare services industry.
Operational Efficiency
Record-high clinic visits per day demonstrate operational efficiency and capacity utilization, enhancing profitability and supporting sustainable growth.
Cash Flow Generation
The 8.54% growth in free cash flow highlights strong cash generation, providing financial flexibility for reinvestment and strategic initiatives.
Negative Factors
Medicare Rate Reductions
Ongoing Medicare rate reductions pose a significant risk to revenue and profitability, potentially impacting long-term financial stability and growth.
Staffing Challenges
Staffing challenges in certain markets can hinder operational efficiency and growth, affecting service delivery and patient satisfaction over time.
Policy Change Impact
Policy changes by major payers, such as in Michigan, can adversely affect reimbursement rates, impacting revenue and profitability in key markets.

US Physical Therapy (USPH) vs. SPDR S&P 500 ETF (SPY)

US Physical Therapy Business Overview & Revenue Model

Company DescriptionU.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.
How the Company Makes MoneyUS Physical Therapy generates revenue primarily through the provision of outpatient physical therapy services. The company's revenue model is based on billing insurance companies and patients for therapy sessions, which typically involve direct billing to Medicare, Medicaid, and private health insurance plans. Key revenue streams include reimbursement for therapy services provided, management fees from clinics that are part of its network, and income from ancillary services such as diagnostic imaging. Additionally, USPH's strategic partnerships with healthcare providers and hospitals contribute to its earnings by increasing patient referrals and expanding its service offerings, thereby enhancing its overall financial performance.

US Physical Therapy Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Positive
The earnings call reflected a largely positive sentiment, with significant revenue growth, record operational metrics, and improved guidance. However, challenges remain with Medicare rate reductions and staffing issues in some markets.
Q2-2025 Updates
Positive Updates
Record Visits Per Clinic
Achieved a company record of 32.7 average visits per clinic per day, the highest in company history.
Strong Revenue Growth
Physical therapy revenues increased by 17.3% to $168.3 million compared to the same period last year.
Injury Prevention Revenue Surge
Injury prevention net revenues increased by 22.6% compared to the second quarter of 2024.
Net Promoter Score Achievement
Achieved a Net Promoter Score of 93.5, significantly higher than the excellent benchmark of 50 for healthcare companies.
Positive Adjusted EBITDA Growth
Adjusted EBITDA increased to $26.9 million, up $4.7 million from the second quarter of last year.
Increased Guidance
Raised full-year 2025 adjusted EBITDA guidance to a range of $93 million to $97 million.
Negative Updates
Medicare Rate Headwinds
Continued impact from Medicare rate reductions, with a $25 million impact from stacked cuts.
Staffing Challenges in Certain Markets
Some markets still facing staffing tightness affecting same-store growth in mature facilities.
Impact of Michigan Payer Policy Change
Largest payer in Michigan implemented a policy change negatively impacting net rate.
Company Guidance
During the U.S. Physical Therapy Second Quarter 2025 Earnings Call, the company increased its full-year adjusted EBITDA guidance to a range of $93 million to $97 million, reflecting strong performance and growth. The company achieved a record average of 32.7 visits per clinic per day, up from 30.6 in the previous year, and reported a Net Promoter Score of 93.5, indicating high patient satisfaction. Revenues in physical therapy increased by 17.3%, and industrial injury prevention revenues grew by 22.6%. Despite a slight increase in salaries and related costs by 0.7%, the overall operating cost per visit decreased. The company added over 50 net clinics year-over-year and exceeded 3 million visits in the first half of the year. Gross profit margins improved to 21.1%, and adjusted EBITDA for the quarter was $26.9 million, up from $22.2 million last year. The company also announced a share repurchase program of up to $25 million through 2026.

US Physical Therapy Financial Statement Overview

Summary
US Physical Therapy presents a stable financial profile with strengths in cash flow generation and operational efficiency. The income statement shows some revenue growth challenges, but the balance sheet remains robust with manageable leverage. The company's ability to generate cash flow supports its financial health, positioning it well for future growth opportunities.
Income Statement
65
Positive
US Physical Therapy's income statement shows a mixed performance. The TTM data indicates a slight decline in revenue growth, but the company maintains a healthy gross profit margin of 20.37% and a net profit margin of 4.76%. The EBIT and EBITDA margins are also stable, suggesting efficient operations. However, the negative revenue growth rate in the latest period is a concern.
Balance Sheet
70
Positive
The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.61, indicating manageable leverage. The return on equity (ROE) is 6.43%, which is modest but shows improvement over previous periods. The equity ratio is stable, suggesting a balanced asset structure. Overall, the company maintains a solid balance sheet with room for improvement in equity returns.
Cash Flow
75
Positive
Cash flow analysis reveals a positive trajectory with an 8.54% growth in free cash flow. The operating cash flow to net income ratio is 0.60, and the free cash flow to net income ratio is 0.85, indicating strong cash generation relative to earnings. The company demonstrates effective cash management, enhancing its financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue665.21M671.35M604.80M553.14M495.02M422.97M
Gross Profit135.52M123.92M111.99M112.02M117.18M94.45M
EBITDA101.40M86.91M74.37M76.09M85.73M77.68M
Net Income31.68M26.46M14.67M43.41M57.92M52.49M
Balance Sheet
Total Assets1.18B1.17B997.24M858.15M749.43M594.36M
Cash, Cash Equivalents and Short-Term Investments34.09M41.36M152.82M31.59M28.57M32.92M
Total Debt305.40M295.23M258.59M295.34M223.08M110.99M
Total Liabilities414.01M408.42M345.00M373.59M296.98M184.39M
Stockholders Equity500.75M488.93M476.19M315.79M295.61M276.16M
Cash Flow
Free Cash Flow60.87M65.75M72.68M50.29M68.20M92.36M
Operating Cash Flow71.72M74.94M81.98M58.54M76.41M100.00M
Investing Cash Flow-120.03M-149.45M-45.02M-81.27M-124.14M-51.20M
Financing Cash Flow-30.51M-36.95M84.27M25.76M43.38M-39.42M

US Physical Therapy Technical Analysis

Technical Analysis Sentiment
Positive
Last Price83.40
Price Trends
50DMA
80.52
Positive
100DMA
78.23
Positive
200DMA
79.42
Positive
Market Momentum
MACD
-0.14
Negative
RSI
55.98
Neutral
STOCH
86.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USPH, the sentiment is Positive. The current price of 83.4 is above the 20-day moving average (MA) of 81.83, above the 50-day MA of 80.52, and above the 200-day MA of 79.42, indicating a bullish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 55.98 is Neutral, neither overbought nor oversold. The STOCH value of 86.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USPH.

US Physical Therapy Risk Analysis

US Physical Therapy disclosed 31 risk factors in its most recent earnings report. US Physical Therapy reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

US Physical Therapy Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
1.42B12.6713.18%-3.08%
74
Outperform
877.87M32.488.56%30.58%24.86%
70
Outperform
$1.27B36.107.02%2.15%16.24%116.58%
69
Neutral
1.57B11.638.21%2.02%-16.10%-48.97%
68
Neutral
1.18B115.622.27%5.17%-65.33%
54
Neutral
723.18M-2.43-49.02%-14.33%-398.68%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
USPH
US Physical Therapy
83.40
0.62
0.75%
AMN
AMN Healthcare Services
18.87
-23.52
-55.48%
HCSG
Healthcare Services
16.36
5.19
46.46%
MD
Pediatrix Medical Group
16.30
4.71
40.64%
SEM
Select Medical
12.64
-5.84
-31.60%
PNTG
Pennant Group
25.40
-10.30
-28.85%

US Physical Therapy Corporate Events

Business Operations and Strategy
US Physical Therapy Updates Investor Presentation
Neutral
Aug 12, 2025

On August 12, 2025, U.S. Physical Therapy Inc. updated its investor presentation, which is available on the company’s website. The update provides an overview of the company, but the information is not considered filed under the Securities Exchange Act of 1934 and is not incorporated by reference into any other filings.

The most recent analyst rating on (USPH) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on US Physical Therapy stock, see the USPH Stock Forecast page.

Financial DisclosuresRegulatory Filings and Compliance
US Physical Therapy Discusses Q2 2025 Financial Results
Neutral
Aug 11, 2025

On August 7, 2025, U.S. Physical Therapy Inc. held a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2025. The transcript of the call was made available as part of a Current Report on Form 8-K, although it will not be considered filed for purposes of the Securities Exchange Act of 1934.

The most recent analyst rating on (USPH) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on US Physical Therapy stock, see the USPH Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
US Physical Therapy Reports Record Q2 2025 Results
Positive
Aug 7, 2025

On August 6, 2025, U.S. Physical Therapy, Inc. reported record results for the second quarter of 2025, with significant increases in patient visits and revenue. The company saw a 21.4% rise in Adjusted EBITDA to $26.9 million and a 17.3% increase in total revenue to $168.3 million, driven by higher patient visits and strategic acquisitions. The company also raised its full-year 2025 guidance for Adjusted EBITDA, reflecting strong operational performance and growth in its injury prevention business.

The most recent analyst rating on (USPH) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on US Physical Therapy stock, see the USPH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 25, 2025